A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis ...

UCB, a global biopharmaceutical company, today announced two-year data from the BE HEARD^ trials for BIMZELX® (bimekizumab-bkzx) in moderate to severe hidradenitis suppurativa (HS). Bimekizumab-bkzx, ...

Prophylactic measures such as vancomycin, povidone-iodine and saline irrigation yielded similar rates of periprosthetic joint infection and wound complications at 3 months for high-risk patients ...

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...

Incyte (INCY) announced topline results from its Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib, an ...

In the case described in the Equine Veterinary Education Journal, x-rays and hoof testers were not able to predict the location of a subsolar abscess in this horse's foot ...

Among 821 patients assigned to the four groups, no statistically significant differences were noted in rates of persistent wound drainage or dehiscence, cellulitis or abscess, 3-month infection ...

The cause of most concern are seed oils - a type of vegetable oil derived from plant seeds but the cause of most concern are ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.